Yaron Pereg

Yaron Pereg

Company: Kahr Medical

Job title: Chief Executive Officer


Executive leader with over a decade of experience leading worldwide pre-clinical and clinical programs in oncology, heading multi-disciplinary teams and managing multi-million-dollar budgets in private and publicly traded companies. CEO of KAHR Medical, a privately-held biotechnology company developing a novel drug platform based on, bi-functional, immunotherapeutic fusion proteins, targeting multiple cancer indications. Prior to joining KAHR Medical, served as Chief Development Officer at Cellect Biotechnology (NASDAQ: APOP) and as Senior Director of Oncology at BioLineRx (NASDAQ: BLRX). Holds a Ph.D. in Molecular Genetics and Biochemistry from the Tel-Aviv University and was a post-doctoral fellow at Genentech, a leading biotechnology company, member of the Roche Group.


DSP107 – A First-In-Class Bi-Functional CD47x41BB Targeting Compound 12:15 pm

Download The Full Event Guide Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.